- Home
- ANVS
ANVS
Annovis Bio Inc.
as 05-10-2024 4:00pm EST
$.
-
$.
-.%
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 66.5M | IPO Year: | 2020 |
| Target Price: | $17.50 | AVG Volume (30 days): | 493.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.79 - $22.49 | Next Earning Date: | 05-21-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Annovis Bio Inc. News
ANVS Breaking Stock News: Dive into ANVS Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Zacks
a day ago
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Zacks
2 days ago
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
GlobeNewswire
2 days ago
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
Zacks
2 days ago
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Zacks
3 days ago
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
Zacks
3 days ago
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
Zacks
4 days ago